JP2012515213A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012515213A5 JP2012515213A5 JP2011546329A JP2011546329A JP2012515213A5 JP 2012515213 A5 JP2012515213 A5 JP 2012515213A5 JP 2011546329 A JP2011546329 A JP 2011546329A JP 2011546329 A JP2011546329 A JP 2011546329A JP 2012515213 A5 JP2012515213 A5 JP 2012515213A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- individual
- combination
- antigen
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14453709P | 2009-01-14 | 2009-01-14 | |
| US61/144,537 | 2009-01-14 | ||
| US29309610P | 2010-01-07 | 2010-01-07 | |
| US61/293,096 | 2010-01-07 | ||
| PCT/US2010/021029 WO2010083298A1 (en) | 2009-01-14 | 2010-01-14 | Methods and compositions containing mtor inhibitors for enhancing immune responses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012515213A JP2012515213A (ja) | 2012-07-05 |
| JP2012515213A5 true JP2012515213A5 (enExample) | 2012-12-27 |
Family
ID=42340082
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011546329A Pending JP2012515213A (ja) | 2009-01-14 | 2010-01-14 | 免疫応答を増強するための、ｍＴＯＲ阻害剤を含有する方法及び組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20100196311A1 (enExample) |
| EP (1) | EP2375897A4 (enExample) |
| JP (1) | JP2012515213A (enExample) |
| CN (1) | CN102281761A (enExample) |
| CA (1) | CA2748931A1 (enExample) |
| WO (1) | WO2010083298A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011133636A1 (en) | 2010-04-20 | 2011-10-27 | Cedars-Sinai Medical Center | COMBINATION THERAPY WITH CD4 LYMPHOCYTE DEPLETION AND mTOR INHIBITORS |
| CN104338129B (zh) * | 2013-07-26 | 2017-05-24 | 中国科学院上海巴斯德研究所 | 雷帕霉素作为疫苗佐剂的用途及制备方法 |
| JP2016537345A (ja) * | 2013-11-13 | 2016-12-01 | ノバルティス アーゲー | 免疫応答を増強するためのｍＴＯＲ阻害剤 |
| CN105979961B (zh) | 2014-02-05 | 2020-12-18 | 西达-赛奈医疗中心 | 用于治疗癌症和感染性疾病的方法和组合物 |
| KR102612313B1 (ko) | 2014-07-21 | 2023-12-12 | 노파르티스 아게 | 인간화 항-bcma 키메라 항원 수용체를 사용한 암의 치료 |
| CN107109420A (zh) | 2014-07-21 | 2017-08-29 | 诺华股份有限公司 | 使用cll－1嵌合抗原受体的癌症治疗 |
| WO2016185443A1 (en) | 2015-05-20 | 2016-11-24 | Novartis Ag | Pharmaceutical combination of everolimus with dactolisib |
| CA2990705A1 (en) * | 2015-06-29 | 2017-01-05 | Abraxis Bioscience, Llc | Methods of treating hematological malignancy using nanoparticle mtor inhibitor combination therapy |
| HUE070408T2 (hu) | 2015-06-29 | 2025-06-28 | Abraxis Bioscience Llc | Szirolimuszt és albumint tartalmazó nanorészecskék epitelioid sejtes tumorok kezelésében történõ alkalmazásra |
| EP3324983A4 (en) | 2015-07-20 | 2019-04-10 | Mayo Foundation for Medical Education and Research | METHOD AND MATERIALS FOR PRODUCING T-CELLS |
| CN116376826A (zh) | 2016-01-20 | 2023-07-04 | 菲特治疗公司 | 用来在过继性免疫疗法中进行免疫细胞调节的组合物和方法 |
| US11413309B2 (en) * | 2016-01-20 | 2022-08-16 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
| CA3044355A1 (en) | 2016-11-23 | 2018-05-31 | Novartis Ag | Methods of enhancing immune response with everolimus, dactolisib or both |
| EP3548049A4 (en) * | 2016-12-05 | 2020-07-22 | Fate Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR MODULATION OF IMMUNE CELLS IN ADOPTIVE IMMUNOTHERAPIES |
| WO2019157516A1 (en) | 2018-02-12 | 2019-08-15 | resTORbio, Inc. | Combination therapies |
| CA3100724A1 (en) | 2018-06-13 | 2019-12-19 | Novartis Ag | B-cell maturation antigen protein (bcma) chimeric antigen receptors and uses thereof |
| CN110412289B (zh) * | 2019-07-25 | 2022-08-02 | 北京美迪阿姆科技发展有限公司 | 抑制性t细胞及筛选方法和抑制自身免疫反应中的应用 |
| CN114426952A (zh) * | 2020-10-29 | 2022-05-03 | 中国科学技术大学 | 用于白血病的car t细胞疗法的t细胞增效剂及获得增效t细胞的方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3066599A (en) * | 1998-03-03 | 1999-10-18 | University Of Southern California | Use of cytokines and mitogens to inhibit graft versus host disease |
| US7198789B2 (en) * | 1998-03-17 | 2007-04-03 | Genetics Institute, Llc | Methods and compositions for modulating interleukin-21 receptor activity |
| US7718196B2 (en) * | 2001-07-02 | 2010-05-18 | The United States Of America, As Represented By The Department Of Health And Human Services | Rapamycin-resistant T cells and therapeutic uses thereof |
| WO2005003335A2 (en) * | 2003-06-12 | 2005-01-13 | Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Rapamycin resistant t cells and therapeutic uses thereof |
| AU2002342299A1 (en) * | 2001-10-31 | 2003-05-12 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of | Generation of use of tc1 and tc2 cells |
| WO2004004644A2 (en) * | 2002-07-05 | 2004-01-15 | Beth Israel Deaconess Medical Center | Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms |
| DE60218173T2 (de) * | 2002-10-11 | 2007-11-22 | Sentoclone Ab | Immuntherapie für Krebs |
| KR20080108517A (ko) * | 2006-04-05 | 2008-12-15 | 노파르티스 아게 | 암을 치료하기 위한 치료제의 조합물 |
| US8119772B2 (en) * | 2006-09-29 | 2012-02-21 | California Institute Of Technology | MART-1 T cell receptors |
| EP3293266B1 (en) * | 2007-05-04 | 2025-12-24 | University Health Network | Il-12 immunotherapy for cancer |
| US8840899B2 (en) * | 2008-08-05 | 2014-09-23 | Emory University | Use of mTOR inhibitors to enhance T cell immune responses |
-
2010
- 2010-01-14 CN CN2010800048759A patent/CN102281761A/zh active Pending
- 2010-01-14 CA CA2748931A patent/CA2748931A1/en not_active Abandoned
- 2010-01-14 US US12/687,650 patent/US20100196311A1/en not_active Abandoned
- 2010-01-14 EP EP10732083.0A patent/EP2375897A4/en not_active Withdrawn
- 2010-01-14 WO PCT/US2010/021029 patent/WO2010083298A1/en not_active Ceased
- 2010-01-14 JP JP2011546329A patent/JP2012515213A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012515213A5 (enExample) | ||
| Khosravi et al. | Immunologic tumor microenvironment modulators for turning cold tumors hot | |
| Yang et al. | Interaction between intestinal microbiota and tumour immunity in the tumour microenvironment | |
| Dzutsev et al. | Microbes and cancer | |
| Liu et al. | Tissue immune cells fuel obesity-associated inflammation in adipose tissue and beyond | |
| Shan et al. | Mechanism and strategies of immunotherapy resistance in colorectal cancer | |
| Wang et al. | Modulation of gut microbiota: a novel paradigm of enhancing the efficacy of programmed death-1 and programmed death ligand-1 blockade therapy | |
| Song et al. | Umbilical cord-derived mesenchymal stem cell extracts reduce colitis in mice by re-polarizing intestinal macrophages | |
| US9730967B2 (en) | Method and system for treating cancer cachexia | |
| Bobrowicz et al. | Pathogenesis and therapy of primary cutaneous T-cell lymphoma: Collegium Internationale Allergologicum (CIA) update 2020 | |
| JP2015134813A5 (enExample) | ||
| JP2019512020A5 (enExample) | ||
| US20200323905A1 (en) | Methods and compositions for modulating the immune system | |
| Chen et al. | Low-dose irradiation of the gut improves the efficacy of PD-L1 blockade in metastatic cancer patients | |
| Hu et al. | Inhibition of the PD-1/PD-L1 signaling pathway enhances innate immune response of alveolar macrophages to mycobacterium tuberculosis in mice | |
| JP2013541010A5 (enExample) | ||
| Zou et al. | Chemokines in progression, chemoresistance, diagnosis, and prognosis of colorectal cancer | |
| Viudez-Pareja et al. | Immunomodulatory properties of the lymphatic endothelium in the tumor microenvironment | |
| Pai et al. | Therapeutic benefit of bortezomib on acute graft-versus-host disease is tissue specific and is associated with interleukin-6 levels | |
| Xie et al. | Loss of the innate immunity negative regulator IRAK-M leads to enhanced host immune defense against tumor growth | |
| Gras et al. | The inhibition of Th17 immune response in vitro and in vivo by the carbosilane dendrimer 2G-NN16 | |
| Chandwaskar et al. | Dysregulation of T cell response in the pathogenesis of inflammatory bowel disease | |
| Qi et al. | P. aeruginosa mediated necroptosis in mouse tumor cells induces long-lasting systemic antitumor immunity | |
| Yue et al. | Harnessing CD8+ T cell dynamics in hepatitis B virus‐associated liver diseases: Insights, therapies and future directions | |
| Nobel et al. | STAT signaling in the intestine |